By transcriptome sequencing of clinical glioma samples of p53 mutants (19NS, 84NS, 157NS, and 528NS), the results showed that p53 mutants could promote the upregulation of inflammatory factor CCL2 and chemotactic gene tumor necrosis factor-α expression in glioma (Ham et al., 2019). This evidence concerns the gene TP53 and central nervous system cancer.